MNPR (Monopar Therapeutics) FCF Margin %: 0.00% (As of Mar. 2026)


MNPR Monopar Therapeutics Inc MNPR
35 GF Score
Price $89.10
! 2 Warning Signs
View Full Analysis

What is Monopar Therapeutics FCF Margin %?

Monopar Therapeutics MNPR +9.14% 35 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates MNPR with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 960 Biotechnology companies, Monopar Therapeutics ranks worse than 104166.56% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Monopar Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-3.47 Mil. Monopar Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Monopar Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Monopar Therapeutics's current FCF Yield % is -1.68%.

The historical rank and industry rank for Monopar Therapeutics's FCF Margin % or its related term are showing as below:


MNPR's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -85.21
* Ranked among companies with meaningful FCF Margin % only.

Monopar Therapeutics FCF Margin % Related Terms

Monopar Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Monopar Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Monopar Therapeutics FCF Margin % Chart

Monopar Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Monopar Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MNPR vs IPSC, ADCT, CMPX: FCF Margin % Comparison

For the Biotechnology subindustry, Monopar Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Monopar Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Monopar Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Monopar Therapeutics's FCF Margin % falls into.


MNPR
35GF Score
Monopar Therapeutics Inc MNPR
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Monopar Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Monopar Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-12.201/0
= %

Monopar Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-3.474/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Monopar Therapeutics (MNPR) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Monopar Therapeutics and its competitors. According to the industry distribution chart, Monopar Therapeutics ranks #999999 out of 960 companies in the Biotechnology industry.
Is Monopar Therapeutics' FCF Margin % too high?
Monopar Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, Monopar Therapeutics ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Monopar Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Monopar Therapeutics' FCF Margin % compare to IPSC and ADCT?
According to the Biotechnology industry distribution chart, Monopar Therapeutics ranks #999999 out of 960 companies for FCF Margin %. This places Monopar Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Monopar Therapeutics and its competitors. Monopar Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monopar Therapeutics stock overvalued right now?
Monopar Therapeutics (MNPR) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Monopar Therapeutics' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Monopar Therapeutics (MNPR), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Monopar Therapeutics Business Description

Address 1000 Skokie Boulevard, Suite 350, Wilmette, IL, USA, 60091
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
35GF Score

Get the complete analysis for MNPR

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$89.10
Price